Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts
Benzinga Insights 8 months ago
Analyst Ratings
5 analysts have shared their evaluations of Ligand Pharmaceuticals (NASDAQ:LGND) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Ligand Pharmaceuticals, presenting an average target of $250.2, a high estimate of $277.00, and a low estimate of $230.00. Marking an increase of 4.25%, the current average surpasses the previous average price target of $240.00.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Ligand Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Trevor Allred | Oppenheimer | Raises | Outperform | $277.00 | $275.00 |
| Joseph Pantginis | HC Wainwright & Co. | Raises | Buy | $239.00 | $231.00 |
| Douglas Miehm | RBC Capital | Raises | Outperform | $235.00 | $234.00 |
| Annabel Samimy | Stifel | Raises | Buy | $230.00 | $220.00 |
| Yigal Nochomovitz | Citigroup | Announces | Buy | $270.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ligand Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ligand Pharmaceuticals compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ligand Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ligand Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Ligand Pharmaceuticals analyst ratings.
Delving into Ligand Pharmaceuticals's Background
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Key Indicators: Ligand Pharmaceuticals's Financial Health
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Ligand Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 122.85%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ligand Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 101.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ligand Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Ligand Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 9.67%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.47, Ligand Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.